EA201890142A1 - Замещенные пиримидиновые обратные ингибиторы bmi-1 - Google Patents

Замещенные пиримидиновые обратные ингибиторы bmi-1

Info

Publication number
EA201890142A1
EA201890142A1 EA201890142A EA201890142A EA201890142A1 EA 201890142 A1 EA201890142 A1 EA 201890142A1 EA 201890142 A EA201890142 A EA 201890142A EA 201890142 A EA201890142 A EA 201890142A EA 201890142 A1 EA201890142 A1 EA 201890142A1
Authority
EA
Eurasian Patent Office
Prior art keywords
bmi
substituted pyrimidine
reduce
inhibit
function
Prior art date
Application number
EA201890142A
Other languages
English (en)
Other versions
EA035349B1 (ru
Inventor
Чан-Сун Ли
Рамиль Байазитов
Лянсянь Цао
Томас У. Дэвис
У Ду
Жунган Лю
Йоунг-Чоон Моон
Стивен Д. Пэджет
Хунюй Жэнь
Надя Сидоренко
Ричард Джеральд Уайлде
Original Assignee
ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ПиТиСи ТЕРАПЬЮТИКС, ИНК. filed Critical ПиТиСи ТЕРАПЬЮТИКС, ИНК.
Publication of EA201890142A1 publication Critical patent/EA201890142A1/ru
Publication of EA035349B1 publication Critical patent/EA035349B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hematology (AREA)
  • Oncology (AREA)

Abstract

В настоящей заявке описаны аминзамещенные обратные пиримидиновые соединения и их формы, которые ингибируют функцию и снижают уровень B-клеточного специфического сайта интеграции 1 вируса мышиного лейкоза Молони (Bmi-1), и способы их использования для ингибирования функции Bmi-1 и снижения уровня Bmi-1 для лечения рака, опосредованного Bmi-1.
EA201890142A 2012-11-21 2013-11-21 ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1 EA035349B1 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261728907P 2012-11-21 2012-11-21

Publications (2)

Publication Number Publication Date
EA201890142A1 true EA201890142A1 (ru) 2018-06-29
EA035349B1 EA035349B1 (ru) 2020-05-29

Family

ID=50776672

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201890142A EA035349B1 (ru) 2012-11-21 2013-11-21 ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1
EA201590992A EA031405B1 (ru) 2012-11-21 2013-11-21 Замещенные пиримидиновые обратные ингибиторы bmi-1

Family Applications After (1)

Application Number Title Priority Date Filing Date
EA201590992A EA031405B1 (ru) 2012-11-21 2013-11-21 Замещенные пиримидиновые обратные ингибиторы bmi-1

Country Status (32)

Country Link
US (3) US10428050B2 (ru)
EP (1) EP2922828B1 (ru)
JP (3) JP6412503B2 (ru)
KR (4) KR20220143164A (ru)
CN (2) CN111423417B (ru)
AR (1) AR093579A1 (ru)
AU (1) AU2013348009C1 (ru)
BR (1) BR112015011760B1 (ru)
CA (1) CA2892045C (ru)
CL (1) CL2015001377A1 (ru)
CR (1) CR20150294A (ru)
CU (1) CU24387B1 (ru)
DK (1) DK2922828T3 (ru)
EA (2) EA035349B1 (ru)
EC (1) ECSP15019948A (ru)
ES (1) ES2821529T3 (ru)
HK (1) HK1215032A1 (ru)
IL (2) IL238871B (ru)
MA (1) MA38208B1 (ru)
MX (2) MX2015006469A (ru)
NI (1) NI201500072A (ru)
NZ (2) NZ746607A (ru)
PE (1) PE20151413A1 (ru)
PH (1) PH12015501130A1 (ru)
PL (1) PL2922828T3 (ru)
PT (1) PT2922828T (ru)
SA (1) SA517381847B1 (ru)
SG (2) SG11201503982XA (ru)
TW (1) TWI623531B (ru)
UA (1) UA118094C2 (ru)
WO (1) WO2014081906A2 (ru)
ZA (1) ZA201503642B (ru)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035349B1 (ru) * 2012-11-21 2020-05-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1
US9579324B2 (en) 2013-07-11 2017-02-28 Agios Pharmaceuticals, Inc Therapeutically active compounds and their methods of use
JP6529492B2 (ja) * 2013-07-11 2019-06-12 アジオス ファーマシューティカルズ， インコーポレイテッド 癌の処置のためのｉｄｈ２突然変異体阻害剤としての２，４−または４，６−ジアミノピリミジン化合物
WO2015003360A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
WO2015003355A2 (en) 2013-07-11 2015-01-15 Agios Pharmaceuticals, Inc. Therapeutically active compounds and their methods of use
EA034866B1 (ru) 2013-08-30 2020-03-31 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Замещенные пиримидиновые ингибиторы bmi-1
US10584115B2 (en) 2013-11-21 2020-03-10 Ptc Therapeutics, Inc. Substituted pyridine and pyrazine BMI-1 inhibitors
US10874355B2 (en) 2014-04-24 2020-12-29 Cognoa, Inc. Methods and apparatus to determine developmental progress with artificial intelligence and user input
US10851082B2 (en) 2015-10-28 2020-12-01 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)
US11972336B2 (en) 2015-12-18 2024-04-30 Cognoa, Inc. Machine learning platform and system for data analysis
EP3402780A1 (en) * 2016-01-14 2018-11-21 Beth Israel Deaconess Medical Center, Inc. Mast-cell modulators and uses thereof
AU2018219846A1 (en) * 2017-02-09 2019-09-12 Cognoa, Inc. Platform and system for digital personalized medicine
WO2019028171A1 (en) 2017-08-01 2019-02-07 Ptc Therapeutics, Inc. DHODH INHIBITOR FOR USE IN THE TREATMENT OF HEMATOLOGICAL CANCERS
EP3564235A1 (en) * 2018-05-03 2019-11-06 Northwestern University Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (mnk1) and 2 (mnk2)
AU2019340402A1 (en) 2018-08-17 2021-03-25 Ptc Therapeutics, Inc. Method for treating pancreatic cancer
CN109988172B (zh) * 2019-01-10 2020-09-29 石家庄学院 一种吡唑并[1,5-a]嘧啶类杂环化合物及衍生物的合成方法
EP3911418A1 (en) 2019-01-15 2021-11-24 PTC Therapeutics, Inc. Method for treating an acute myeloid leukemia
CA3131249A1 (en) * 2019-02-28 2020-09-03 Ptc Therapeutics, Inc. 5-fluoro-2-(6fluoro-2-methyl-1h-benzo(d)imidazol-1-yl)-n4-(4-(trifluoromethyl)phenyl)pyrimidine-4,6-diamine dor treating a multiple myeloma
HUE062796T2 (hu) * 2019-03-11 2023-12-28 Ptc Therapeutics Inc Megnövelt biológiai hozzáférhetõséggel rendelkezõ vegyületforma és annak készítményei
MX2021011493A (es) 2019-03-22 2022-01-04 Cognoa Inc Métodos y dispositivos de terapia digital personalizados.
EP3947379A4 (en) * 2019-03-27 2022-12-21 PTC Therapeutics, Inc. COMBINATIONS FOR USE IN A METHOD OF TREATMENT OF SARCOMA
US20220177459A1 (en) * 2019-04-02 2022-06-09 Hinova Pharmaceuticals Inc. Aromatic amine compound and use thereof in preparation of ar and brd4 dual inhibitors and regulators

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH593266A5 (ru) 1973-09-20 1977-11-30 Delalande Sa
AU688087B2 (en) * 1994-08-13 1998-03-05 Yuhan Corporation Novel pyrimidine derivatives and processes for the preparation thereof
IN188411B (ru) 1997-03-27 2002-09-21 Yuhan Corp
KR100272471B1 (ko) 1998-11-17 2000-11-15 김선진 신규의 피리미딘 유도체 및 그의 제조방법
GB9905075D0 (en) * 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
ATE253915T1 (de) 1999-06-30 2003-11-15 Merck & Co Inc Src-kinase hemmende verbindungen
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
JP2003512467A (ja) 1999-10-27 2003-04-02 ノバルティス アクチエンゲゼルシャフト チアゾールおよびイミダゾ（４，５−ｂ）ピリジン化合物ならびにそれらの医薬用途
WO2001060816A1 (en) * 2000-02-17 2001-08-23 Amgen Inc. Kinase inhibitors
GB2361236B (en) 2000-03-29 2002-04-24 Cyclacel Ltd Pyrimidines useful against proliferative disorders
WO2002022605A1 (en) 2000-09-15 2002-03-21 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1330452B1 (en) 2000-09-20 2008-11-26 Ortho-McNeil Pharmaceutical, Inc. Pyrazine derivatives as modulators of tyrosine kinases
US6716851B2 (en) * 2000-12-12 2004-04-06 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators or caspases and inducers of apoptosis and the use thereof
AU2002228922A1 (en) * 2000-12-12 2002-06-24 Cytovia, Inc. Substituted 2-aryl-4-arylaminopyrimidines and analogs as activators of caspases and inducers of apoptosis and the use thereof
JP2004515550A (ja) 2000-12-15 2004-05-27 グラクソ グループ リミテッド 治療用化合物
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
ES2316546T3 (es) 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
EP1975620A3 (en) 2001-03-02 2008-12-24 GPC Biotech AG Three hybrid assay system
US7196095B2 (en) 2001-06-25 2007-03-27 Merck & Co., Inc. (Pyrimidinyl) (phenyl) substituted fused heteroaryl p38 inhibiting and PKG kinase inhibiting compounds
ES2271283T3 (es) 2001-07-03 2007-04-16 Vertex Pharmaceuticals Incorporated Isoxazolil-pirimidinas como inhibidores de las proteinas quinasas src y lck.
WO2003011837A1 (en) 2001-08-01 2003-02-13 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003075828A2 (en) 2002-03-11 2003-09-18 Zetiq Technologies Ltd. Compounds useful in the treatment of cancer
NZ537156A (en) 2002-05-23 2007-06-29 Cytopia Pty Ltd Kinase inhibitors
WO2004002963A1 (ja) 2002-06-28 2004-01-08 Nippon Shinyaku Co., Ltd. アミド誘導体及び医薬
GB0215844D0 (en) 2002-07-09 2002-08-14 Novartis Ag Organic compounds
WO2004007407A2 (en) * 2002-07-11 2004-01-22 Fluorous Technologies Incorporated Fluorous tagging and scavenging reactants and methods of synthesis and use thereof
US20040110821A1 (en) * 2002-08-07 2004-06-10 Konkel Michael J. GAL3 receptor antagonists for the treatment of affective disorders
UA80296C2 (en) 2002-09-06 2007-09-10 Biogen Inc Imidazolopyridines and methods of making and using the same
JP2006504755A (ja) 2002-10-15 2006-02-09 スミスクライン ビーチャム コーポレーション Ｇｓｋ−３阻害薬としてのピリダジン化合物
US7169781B2 (en) 2003-10-17 2007-01-30 Hoffmann-La Roche Inc. Imidazole derivatives and their use as pharmaceutical agents
KR101164541B1 (ko) 2004-01-12 2012-07-10 와이엠 바이오사이언시즈 오스트레일리아 피티와이 엘티디 선택적 키나제 저해제
EP1713793A4 (en) 2004-02-04 2009-09-02 Smithkline Beecham Corp PYRIMIDINONE COMPOUNDS SUITED AS KINASEINHIBITORS
CN101676285A (zh) * 2004-03-30 2010-03-24 沃泰克斯药物股份有限公司 用作jak和其它蛋白激酶抑制剂的氮杂吲哚
JP2006045119A (ja) 2004-08-04 2006-02-16 Toray Ind Inc ピラジン誘導体及びそれを有効成分とする腎炎治療薬
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
KR100917511B1 (ko) 2005-02-28 2009-09-16 니뽄 다바코 산교 가부시키가이샤 Ｓｙｋ 저해 활성을 갖는 신규한 아미노피리딘 화합물
EP1858882A1 (en) 2005-03-10 2007-11-28 Bayer Pharmaceuticals Corporation Pyrimidine derivatives for treatment of hyperproliferative disorders
ES2340093T3 (es) 2006-06-22 2010-05-28 Biovitrum Ab (Publ) Derivados pirazina y piridina como inhibidores de cinasa mnk.
EP2074113A1 (en) * 2006-10-03 2009-07-01 NeuroSearch A/S Indazolyl derivatives useful as potassium channel modulating agents
CN101516873A (zh) * 2006-10-03 2009-08-26 神经研究公司 用作钾通道调节剂的吲唑基衍生物
ZA200902384B (en) 2006-10-19 2010-07-28 Signal Pharm Llc Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors
BRPI0720635A2 (pt) 2006-12-22 2014-01-07 Novartis Ag Compostos orgânicos e seus usos
PE20081636A1 (es) 2007-01-26 2009-01-10 Smithkline Beecham Corp Inhibidores de antranilamida para aurora quinasa
WO2008099210A2 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
WO2008132502A1 (en) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
GB0714573D0 (en) 2007-07-26 2007-09-05 Imp Innovations Ltd Marker gene
EP2203436A1 (en) 2007-09-17 2010-07-07 Neurosearch A/S Pyrazine derivatives and their use as potassium channel modulators
AU2008321046B2 (en) 2007-11-16 2013-10-24 Incyte Holdings Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
PT2231636E (pt) 2007-12-07 2012-01-02 Novartis Ag Derivados de pirazole e a sua utilização a título de inibidores de quinases dependentes de ciclina
DE102008005493A1 (de) 2008-01-22 2009-07-23 Merck Patent Gmbh 4-(Pyrrolo[2,3-c] pyridine-3-yl)-pyrimidin-2-yl-amin-derivate
GB0801416D0 (en) 2008-01-25 2008-03-05 Piramed Ltd Pharmaceutical compounds
WO2009131687A2 (en) 2008-04-22 2009-10-29 Portola Pharmaceuticals, Inc. Inhibitors of protein kinases
EP2306836B1 (en) 2008-07-01 2016-09-07 PTC Therapeutics, Inc. Bmi-1 protein expression modulators
WO2010016005A1 (en) 2008-08-06 2010-02-11 Pfizer Inc. 6 substituted 2-heterocyclylamino pyrazine compounds as chk-1 inhibitors
EP2331527A1 (en) * 2008-09-02 2011-06-15 NeuroSearch A/S Pyrazolyl-pyrimidine derivatives and their use as potassium channel modulators
WO2010061903A1 (ja) * 2008-11-27 2010-06-03 塩野義製薬株式会社 Pi3k阻害活性を有するピリミジン誘導体およびピリジン誘導体
JPWO2010092962A1 (ja) 2009-02-12 2012-08-16 アステラス製薬株式会社 へテロ環誘導体
CA2756067A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
US8536180B2 (en) 2009-05-27 2013-09-17 Abbvie Inc. Pyrimidine inhibitors of kinase activity
TW201102387A (en) 2009-06-08 2011-01-16 Medicinova Inc Substituted pyrazolo[1,5-a]pyridine compounds having multi-target activity
NZ619259A (en) * 2009-06-17 2015-07-31 Vertex Pharma Inhibitors of influenza viruses replication
EP2532659A1 (en) 2009-07-07 2012-12-12 Pathway Therapeutics, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
WO2011008915A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
WO2011008830A1 (en) 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyrazine inhibitors of kinases
JP2011136925A (ja) 2009-12-28 2011-07-14 Dainippon Sumitomo Pharma Co Ltd 含窒素二環性化合物
CN102812022B (zh) 2010-01-12 2016-02-03 Ab科学有限公司 噻唑和噁唑激酶抑制剂
UY33213A (es) * 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
ES2365960B1 (es) * 2010-03-31 2012-06-04 Palobiofarma, S.L Nuevos antagonistas de los receptores de adenosina.
WO2012022725A2 (en) * 2010-08-19 2012-02-23 F. Hoffmann-La Roche Ag Conversion of somatic cells to induced reprogrammed neural stem cells (irnscs)
AU2011303978B2 (en) 2010-09-13 2014-07-03 Novartis Ag Triazine-oxadiazoles
WO2012050884A2 (en) * 2010-09-28 2012-04-19 President And Fellows Of Harvard College Cardiac glycosides are potent inhibitors of interferon-beta gene expression
WO2012078777A1 (en) 2010-12-09 2012-06-14 Amgen Inc. Bicyclic compounds as pim inhibitors
AU2012221925B2 (en) 2011-02-25 2016-05-05 Yuhan Corporation Diaminopyrimidine derivatives and processes for the preparation thereof
CA2840883C (en) * 2011-07-07 2019-07-16 Merck Patent Gmbh Substituted azaheterocycles
US9695228B2 (en) 2012-11-21 2017-07-04 Janssen Biotech, Inc. EGFR and c-Met fibronectin type III domain binding molecules
EA035349B1 (ru) 2012-11-21 2020-05-29 ПиТиСи ТЕРАПЬЮТИКС, ИНК. ЗАМЕЩЕННЫЕ ПИРИМИДИНОВЫЕ ОБРАТНЫЕ ИНГИБИТОРЫ Bmi-1
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders

Also Published As

Publication number Publication date
NZ746607A (en) 2019-11-29
KR102356487B1 (ko) 2022-02-08
EA201590992A1 (ru) 2015-11-30
IL265253A (en) 2019-05-30
AU2013348009C1 (en) 2019-08-08
TW201427972A (zh) 2014-07-16
ZA201503642B (en) 2020-10-28
SA517381847B1 (ar) 2021-07-17
JP6617186B2 (ja) 2019-12-11
CL2015001377A1 (es) 2016-02-19
JP2016504290A (ja) 2016-02-12
BR112015011760B1 (pt) 2022-12-06
EA035349B1 (ru) 2020-05-29
MX2021009892A (es) 2021-09-14
EP2922828A4 (en) 2016-07-27
CA2892045C (en) 2022-05-31
HK1215032A1 (zh) 2016-08-12
KR20150086345A (ko) 2015-07-27
TWI623531B (zh) 2018-05-11
EA031405B1 (ru) 2018-12-28
CR20150294A (es) 2015-08-20
US20200024260A1 (en) 2020-01-23
JP6412503B2 (ja) 2018-10-24
JP2020055815A (ja) 2020-04-09
JP2019031509A (ja) 2019-02-28
CU20150053A7 (es) 2015-11-27
CN111423417A (zh) 2020-07-17
DK2922828T3 (da) 2020-08-31
KR20210088740A (ko) 2021-07-14
KR102275676B1 (ko) 2021-07-12
CN104918919A (zh) 2015-09-16
WO2014081906A3 (en) 2014-07-17
ECSP15019948A (es) 2016-01-29
PT2922828T (pt) 2020-10-12
US11180483B2 (en) 2021-11-23
MX2015006469A (es) 2015-10-29
CA2892045A1 (en) 2014-05-30
NI201500072A (es) 2016-01-18
US20150315182A1 (en) 2015-11-05
PL2922828T3 (pl) 2020-12-28
PE20151413A1 (es) 2015-10-23
BR112015011760A2 (pt) 2017-07-11
CU24387B1 (es) 2019-03-04
WO2014081906A2 (en) 2014-05-30
AR093579A1 (es) 2015-06-10
UA118094C2 (uk) 2018-11-26
AU2013348009A1 (en) 2015-06-04
CN111423417B (zh) 2022-11-15
SG11201503982XA (en) 2015-06-29
KR20220016305A (ko) 2022-02-08
EP2922828B1 (en) 2020-07-08
PH12015501130A1 (en) 2015-08-03
IL238871A0 (en) 2015-07-30
KR102455889B1 (ko) 2022-10-17
KR20220143164A (ko) 2022-10-24
JP6918898B2 (ja) 2021-08-11
EP2922828A2 (en) 2015-09-30
AU2013348009B2 (en) 2018-05-17
ES2821529T3 (es) 2021-04-26
US10428050B2 (en) 2019-10-01
NZ708909A (en) 2019-11-29
US20220064150A1 (en) 2022-03-03
IL238871B (en) 2019-03-31
MA38208B1 (fr) 2021-12-31
SG10201600149VA (en) 2016-02-26

Similar Documents

Publication Publication Date Title
EA201890142A1 (ru) Замещенные пиримидиновые обратные ингибиторы bmi-1
EA201690502A1 (ru) Замещенные пиримидиновые ингибиторы bmi-1
EA201791305A1 (ru) Конденсированные пиримидины для лечения вич
EA202091115A1 (ru) Производные хиназолина, применяемые для лечения вич
MD3390395T2 (ro) Compuși utili ca inhibitori ai kinazei
EA201690268A1 (ru) Замещенные производные хиназолин-4-она
EA201692338A1 (ru) Соединения 5-хлор-дифторметоксифенил-пиразолопиримидина, представляющие собой ингибиторы янус-киназы
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
CR20180057A (es) Nuevos compuestos biciclicos como inhibidores duales de atx/ca.
JO3515B1 (ar) مثبطات fgfr4 بيريميدين
MA40076A (fr) Inhibiteurs de syk
EA201492056A1 (ru) Пиримидиниловые ингибиторы тирозинкиназы
UA113470C2 (xx) Піримідинові та піридинові сполуки та їх застосування
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
EA201790206A1 (ru) Новые 2,5-замещенные пиримидины в качестве ингибиторов pde4
EA201591628A1 (ru) Дейтерированный палбоциклиб
EA201790207A8 (ru) Новые замещенные пиримидиновые соединения
JO3793B1 (ar) مثبطات تيروزين كاينيز بروتون وأساليب استخدامها
EA201690523A1 (ru) Триазолопиридины, композиции и способы их применения
MX2015013414A (es) N-(2-ciano heterociclil)pirazolo piridonas como inhibidores de janus quinasa.
EA201690716A1 (ru) ПИРИДО[2,3-d]ПИРИМИДИН-4-ОНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ ТАНКИРАЗЫ
MX2015013936A (es) Compuestos de pirimidina condensada sustituida.
PH12016500735A1 (en) Substituted pyrimidine compounds and their use as syk inhibitors
EA201691130A1 (ru) Средства и способы противодействия миелопролиферативным или лимфопролиферативным расстройствам
EA201792380A1 (ru) Новые ингибиторы epha4, нацеленные на его лиганд-связывающий домен

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KG TJ TM